Abstract |
Different glucocorticoid preparations modify the immune reaction in different ways. In this paper, the therapeutic efficacy of two glucocorticoids, deflazacort (DFZ) and prednisone (PDN), are discussed in relation to a group of 30 patients with systemic lupus erythematosus (n = 12) or rheumatoid arthritis (n = 18). The disease sub-groups were divided into two arms, one of which was treated with DFZ and one with PDN in a double-blind protocol. The results of this study indicate that DFZ and PDN induced a clinical remission within 1 month which was maintained until the 6th month. Nevertheless, certain immunological modifications, including a significant reduction of the circulating T lymphocyte level and of the CD4/CD8 ratio, which was between 1 and 1,5 during the DFC treatment and between 1 and 2 during the PDN treatment, are more pronounced and more stable with DFZ than with PDN. Moreover, DFZ has a smaller effect on calcium and glucose metabolism than PDN since the serum glucose and calcium level of patients treated with PDN increased respectively from 90 up to 130 mg/dl and from 9,5 to 11,5 mg/dl whereas those of patients treated with DFC remained within the normal range. These findings indicate that DFZ may have advantages over PDN in the treatment of immune-mediated diseases.
|
Authors | M Scudeletti, F Puppo, L Lanza, L Mantovani, O Bosco, A Iudice, B Imbimbo, F Indiveri |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 45 Suppl 1
Pg. S29-34
( 1993)
ISSN: 0031-6970 [Print] Germany |
PMID | 8313931
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents
- Pregnenediones
- deflazacort
- Prednisone
|
Topics |
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Arthritis, Rheumatoid
(drug therapy, immunology)
- CD4-CD8 Ratio
(drug effects)
- Double-Blind Method
- Humans
- Lupus Erythematosus, Systemic
(drug therapy, immunology)
- Middle Aged
- Prednisone
(therapeutic use)
- Pregnenediones
(therapeutic use)
- Remission Induction
|